X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Through the acquisition, Shionogi extends its infectious disease innovation platform with the access to a novel investigational beta-lactamase inhibitor, QPX7728 (xeruborbactam), which is being advanced clinically for infections caused by drug-resistant Gram-negative bacteria.
Lead Product(s): Xeruborbactam,QPX2015
Therapeutic Area: Infections and Infectious Diseases Product Name: QPX7728
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Shionogi
Deal Size: $140.0 million Upfront Cash: $100.0 million
Deal Type: Acquisition June 25, 2023
Details:
ORAvance (Xeruborbactam) an orally-administered combination product that delivers xeruborbactam to treat infections that occur in outpatient and community setting caused by drug-resistant gram-negative bacteria.
Lead Product(s): Xeruborbactam,Meropenem
Therapeutic Area: Infections and Infectious Diseases Product Name: ORAvance
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2022
Details:
New clinical data for β-lactamase inhibitor xeruborbactam (formerly QPX7728) and synthetic lipopeptide QPX9003, represent new potential therapies for patients with drug-resistant infections – notably carbapenem-resistant Acinetobacter, Pseudomonas, and Enterobacterales.
Lead Product(s): Xeruborbactam,QPX2014
Therapeutic Area: Infections and Infectious Diseases Product Name: QPX7728
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2022
Details:
Qpex exercised a $15 million option from the BARDA, to support the advancement of its anti-infective portfolio which includes OMNIvance, ORAvance and QPX9003, into the clinic intended to comprehensively address patient needs in both the inpatient and outpatient settings.
Lead Product(s): Xeruborbactam
Therapeutic Area: Infections and Infectious Diseases Product Name: QPX7728
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Agreement January 05, 2021
Details:
The Phase 1 study will investigate the safety and pharmacokinetics of QPX7728 alone following single and multiple intravenous doses, and in combination with a beta-lactam antibiotic in healthy adult subjects.
Lead Product(s): Xeruborbactam
Therapeutic Area: Infections and Infectious Diseases Product Name: QPX7728
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
